Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Minocycline
Drug ID BADD_D01470
Description Minocycline was first described in the literacture in 1966.[A190681] It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria.[A190723] Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.[A190723] Minocycline was granted FDA approval on 30 June 1971.[L11695]
Indications and Usage Oral and topical minocycline are indicated to treat inflammatory lesions of acne vulgaris.[L11701,L11704,L11719] Subgingival microspheres are indicated as an adjunct treatment in the reduction of pocket depth in adults with periodontitis.[L11716] Oral and intravenous formulations are indicated to treat infections of susceptible microorganisms.[L11707,L11710,L11713] These include rickettsiae, _Mycoplasma pneumoniae_, _Chlamydia trachomatis_, _Chlamydophila psittaci_, _Chlamydia trachomatis_, _Ureaplasma urealyticum_, _Borrelia recurrentis_, _Haemophilus ducreyi_, _Yersinia pestis_, _Francisella tularensis_, _Vibrio cholerae_, _Campylobacter fetus_, _Brucella_ species, _Bartonella bacilliformis_, _Klebsiella granulomatis_, _Escherichia coli_, _Enterobacter aerogenes_, _Shigella_ species, _Acinetobacter_ species, _Haemophilus influenzae_, and _Kelbsiella_ species.[L11710]
Marketing Status approved; investigational
ATC Code A01AB23; D10AF07; J01AA08
DrugBank ID DB01017
KEGG ID D05045
MeSH ID D008911
PubChem ID 54675783
TTD Drug ID D08LTU
NDC Product Code 49884-512; 69489-212; 72356-101; 49884-513; 42291-589; 69489-201; 72356-103; 49884-511; 42291-591
UNII FYY3R43WGO
Synonyms Minocycline | Minox 50 | Aknemin | Aknin-Mino | Aknin Mino | Aknosan | Mynocine | Apo-Minocycline | Apo Minocycline | Arestin | Blemix | Cyclomin | Cyclops | Dentomycin | Dynacin | Icht-Oral | Icht Oral | Klinomycin | Lederderm | Mestacine | Minakne | Mino-Wolff | Mino Wolff | Minocin | Minocin MR | Minoclir | Minocycline Hydrochloride | Hydrochloride, Minocycline | Minocycline Monohydrochloride | Monohydrochloride, Minocycline | Minocycline, (4R-(4 alpha,4a beta,5a beta,12a beta))-Isomer | Minolis | Minomycin | Minoplus | Minotab | Akamin | Akne-Puren | Akne Puren
Chemical Information
Molecular Formula C23H27N3O7
CAS Registry Number 10118-90-8
SMILES CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Deformity08.01.03.022--Not Available
Conjunctival pigmentation06.06.02.0100.001558%Not Available
Paradoxical embolism24.01.01.0310.000118%Not Available
Skin plaque23.03.03.044--Not Available
Bone hyperpigmentation15.02.04.0300.004522%Not Available
Splenic thrombosis24.01.08.006; 01.09.02.0180.000118%Not Available
Oral pigmentation07.05.05.0240.000260%Not Available
Application site acne12.07.01.047; 08.02.01.047; 23.02.01.0090.000401%Not Available
Cardiac valve discolouration02.07.02.0100.000437%Not Available
Central nervous system vasculitis24.12.04.005; 17.08.02.029; 10.02.02.030--Not Available
Dilated cardiomyopathy02.04.01.0170.000118%Not Available
Drug ineffective for unapproved indication08.06.01.038; 12.09.02.0020.000803%Not Available
Fixed eruption23.03.05.008; 10.01.01.037; 08.01.06.0250.000661%Not Available
Giant cell myocarditis10.02.01.075; 02.04.03.0050.000118%Not Available
Graves' disease10.04.08.014; 06.09.04.009; 05.02.02.0090.000531%Not Available
Haemophagocytic lymphohistiocytosis16.32.03.038; 10.02.01.077; 01.05.01.0260.000472%Not Available
Hypersensitivity myocarditis02.04.03.006; 10.01.03.0550.000236%Not Available
Idiopathic intracranial hypertension17.07.02.0110.002420%Not Available
Immunoglobulin G4 related disease10.04.04.028; 15.06.01.020--Not Available
Joint deposit15.01.08.0180.000118%Not Available
Pigment nephropathy20.05.03.025; 01.06.04.0110.000236%Not Available
Renal aneurysm24.02.02.009; 20.01.07.0170.000177%Not Available
Salt craving14.03.01.0150.000236%Not Available
Taste disorder07.14.03.004; 17.02.07.029--Not Available
Therapy non-responder08.06.01.0630.000838%Not Available
Thyroiditis subacute11.07.01.032; 05.02.04.0070.000118%Not Available
Tissue discolouration08.01.03.1030.000578%Not Available
Trichoglossia07.14.01.0210.000401%Not Available
The 14th Page    First    Pre   14    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene